Piscitelli Dominic sold $181K of ORIC

Piscitelli Dominic (Chief Financial Officer) sold 13,400 shares of Oric Pharmaceuticals, Inc. (ORIC) at $13.53 ($0.18M total) on 2026-09-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Piscitelli Dominic
Published Sep 29, 2026, 11:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 11:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ORIC
Bearish
medium confidence
Mentioned
$ORIC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORICBearishLow
01

Why it matters

The disclosed sale reduces the CFO's ownership and may be interpreted as a lack of confidence, potentially prompting short‑term selling pressure.

02

Market read

Primary relevance is to ORIC shareholders; the filing provides fresh insider information that could affect short‑term price action.

03

What to watch

The CFO may be diversifying holdings; the transaction size is small relative to market cap.

Relevance 3/10Novelty 3/10Timing: after‑hours filing on 2026‑09‑29

Background

Form 4 filings disclose insider transactions; a CFO sale is noteworthy for investors monitoring insider activity.

Company-level read

Ticker impact

$ORICBearishMedium confidence
Context

CFO sold 13,400 shares for $181,257 via a 10b5‑1 plan, reducing his stake to 69,828 shares.

Expected impact

likely slight downward pressure as the market prices in the sale

Evidence & confidence

A CFO off‑loading $181k of stock is a material insider transaction for a small‑cap, often interpreted as a negative signal.

Market effects

Minimal impact on the broader biotech sector; only relevant to ORIC investors.

No regional effect beyond the US market.

Limited global relevance.

Counterpoint

The sale could be routine under a pre‑arranged 10b5‑1 plan and not reflect negative sentiment.

Key entities

  • Oric Pharmaceuticals, Inc.

    US‑listed biotech company (NASDAQ: ORIC) whose CFO disclosed a stock sale.

  • Dominic Piscitelli

    Chief Financial Officer of Oric Pharmaceuticals who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo